23andMe to Present Updates on Clinical Immuno-oncology Programs 23ME-00610 and 23ME-01473 at ESMO Congress 2024

Core Insights - 23andMe Holding Co. will present preliminary clinical data on its anti-CD200R1 antibody 23ME-00610 and anti-ULBP6 monoclonal antibody 23ME-01473 at the ESMO Congress 2024 in Barcelona, Spain from September 13 to September 17 [1][2][6] Group 1: Clinical Trial Data - The company will showcase efficacy data for 23ME-00610 in clear-cell renal-cell carcinoma and high tumor microsatellite instability/high tumor mutational burden patient cohorts during the Phase 2a portion of its ongoing Phase 1/2a clinical trial [2][3] - Preliminary data from the Phase 1/2a clinical trial indicates that 23ME-00610 has an acceptable safety profile and shows preliminary clinical benefits in neuroendocrine and ovarian cancer cohorts [3][8] - The Phase 1/2a trial of 23ME-00610 is designed to evaluate its effectiveness as a first-in-class anti-CD200R1 monoclonal antibody targeting advanced solid malignancies [8][9] Group 2: Biomarker Analysis - The company will present analyses on CD200 as a potential tissue-based biomarker associated with the efficacy of 23ME-00610 [1][2] - CD200R1, the target of 23ME-00610, is identified as an immuno-oncology target with implications for immune tolerance and cancer treatment [8][9] Group 3: Preclinical Data - 23andMe will present preclinical data on 23ME-01473, which targets soluble ULBP6 to enhance anti-tumor immunity through NK and T cells [4][10] - The ongoing Phase 1 clinical trial for 23ME-01473 began in March 2024, focusing on its role in restoring immune cell recognition of cancer cells [4][11] Group 4: Company Background - 23andMe utilizes its proprietary database of human genetic and health information, with over 15 million genotyped customers, to identify potential therapeutic targets [5][12] - The company aims to empower a healthier future through genetics-led consumer healthcare and biopharmaceutical innovations [13]